Moxifloxacin Tillomed

Moxifloxacin, the active ingredient in Moxifloxacin Tillomed, is a fluoroquinolone antibiotic presented as an oral dosage form for oral use. It treats community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and skin and skin structure infections in adult patients.

GNH USA supplies Moxifloxacin Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections of the respiratory tract and skin.

Community‑acquired pneumonia: achieves bacterial eradication and clinical improvement in adult patients. Acute bacterial sinusitis: reduces infection and shortens symptom duration. Acute bacterial exacerbation of chronic bronchitis: improves lung function and decreases exacerbation frequency. Skin and skin structure infections: resolves bacterial skin infections and promotes healing.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain - Rash

Serious or Rare Side Effects: - Tendon rupture or inflammation - QT interval prolongation leading to arrhythmia - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Clostridioides difficile‑associated colitis - Hepatic dysfunction - Photosensitivity

Before prescribing Moxifloxacin, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Assess renal function: adjust therapy in patients with significant impairment. Review cardiac history: monitor QT interval in patients with known prolongation. Avoid use in individuals with documented fluoroquinolone allergy. Use with caution in elderly patients due to increased tendon‑rupture risk. Discontinue promptly if signs of tendon pain or inflammation appear. Store at below 25°C: keep in the original pack, protect from moisture.

Moxifloxacin can interact with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Concomitant QT‑prolonging drugs (e.g., quinidine, amiodarone): increased risk of arrhythmia. - Antacids or supplements containing magnesium/aluminum/iron: reduce moxifloxacin absorption. - Warfarin: may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase central nervous system adverse effects. - CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine): may raise moxifloxacin plasma concentrations.